Human beings are big data. We aren’t just 175 pounds of meat and bone. We aren’t just piles of hydrogen and carbon and oxygen. What makes us all different is how it’s all organized and that is information. We can no longer treat people based on simple numbers like weight, pulse, blood pressure, and temperature. What makes us different is much more complicated than that. . . .
→ Read full post: Is Medicine a Big Data Problem?
source: by Timothy Hay
When the Food and Drug Administration told personal-genetics company 23andMe Inc. in November to stop sending consumers detailed information about their DNA, some industry watchers said the move could be a devastating blow to an emerging area of medicine that holds promise for better health outcomes.
But it was more of a flesh wound, said Claremont Creek Ventures Director Ted Driscoll. Though not an investor in 23andMe, he has . . .
→ Read full post: Ted Driscoll’s WSJ interview: 23andMe Flap With FDA Just a Bump in the Road, One Genetics-Testing Investor Says
Our portfolio company NuMedii just announced a groundbreaking collaboration with Thomson Reuters, the world’s leading information provider for businesses. The Thomson Reuters Science division has quietly been aggregating an enormous database of biological, clinical, and pharmacological information over the past few years. As a biotech startup, NuMedii is focused on revolutionizing drug discovery by reducing the incredible inefficiencies and costs involved in small molecule drug development.
The drug development process is . . .
→ Read full post: Thomson Reuters and NuMedii Launch Initiative for Drug Discovery
Our portfolio company Assurex Health, announced recently the publication of a groundbreaking analysis of pharmacogenomic data in the International Review of Psychiatry.
The publication strongly validates the premise that the clinical use of genomic testing to help predict patient response to psychiatric medications significantly improves treatment outcomes. This is a key milestone in the continuing discussions within the Psychiatric community about the value of laboratory testing in . . .
→ Read full post: Assurex Health Publishes Seminal Paper on Pharmacogenomics
Congratulations to our portfolio company NuMedii for a publication today in Cancer Discovery, which discusses the use of its technology by Stanford researchers to identify an antidepressant as a potential treatment for small cell lung cancer.
NuMedii is a pioneer in the future of pharmacology. As medicine becomes more personalized, every individual will get a custom treatment matched to their genetic and proteomic makeup and pathways. The old way of developing . . .
→ Read full post: Numedii discovers repurposed antidepressants have potential to treat small cell lung cancer
Thursday June 20, 2013, Atul Butte, MD, PhD, a Stanford University Professor and entrepreneur is being honored at a formal ceremony in the White House Rose Garden in Washington DC. The Obama Administration is honoring Dr. Butte and several other genomics and molecular biology researchers who have focused on making large and complex sets of biological data open and widely accessible to the larger research community. Butte has been a leader . . .
→ Read full post: NuMedii Founder Atul Butte, MD, PhD honored at White House; Claremont Creek Ventures continues investment in health care Big Data.
The human genome evolved for us as Paleolithic cavemen, arming us to cope with leopards, communicable diseases, infections, parasites and starvation. But modern society has succeeded in taming most of those risks, and now, ironically, our biggest health challenges are largely a byproduct of our success. As we extend our lifespan, cancer and cardiac disease increase in incidence. We confront an epidemic of diabetes and obesity related diseases largely caused by overconsumption and inactivity. Our genome never evolved to benefit obese 70 year olds. Cavemen didn’t typically live past 40 and didn’t drink high-fructose corn syrup in Big Gulps. . . .
→ Read full post: The Golden Age of Healthcare Investing is Now
February 20, 2013 source: the original post by Ed Silverman appeared in Pharmalot
As drug development and diagnostics increasingly converge, the advent of personalized medicine is increasing all the time. Of course, we are not quite there yet, but the advent of electronic medical records and the genome are inching us closer all the time. But this poses challenges, of course, and Ted Driscoll, who heads the digital healthcare team at . . .
→ Read full post: Ted Driscoll featured in Pharmalot, Op-Ed: Entering The Golden Age Of Big Data